University of Chicago Medicine has extended its research partnership with the biopharmaceutical company AbbVie through 2027.
The partnership was established in 2016 and focuses on accelerating outcomes for cancer patients through translational and clinical research, according to a Dec. 17 news release from the health system.
The collaboration will soon benefit from additional infrastructure at the AbbVie Foundation Cancer Pavilion, which is set to open in 2027 as Illinois’ first freestanding cancer center.
Kunle Odunsi, MD, PhD, director of the University of Chicago Medicine Comprehensive Cancer Center and AbbVie Foundation Distinguished Professor, said the partnership provides opportunities for scientific exchange and clinical trial development.
Leave a Reply